COMT and cancer: Combination of EGCG and Tolcapone (TOL) (a COMT inhibitor) was found to improve the bioavailability of EGCG and to synergistically enhance the cancer suppressive effect of EGCG by inhibiting the COMT-mediated methylation of EGCG in vivo [84].